This effect was partially reversible with systemic administration of an IDO inhibitor, holding implications for combining cancer vaccines which utilize tumor specific antigenic peptides to generate a T cell antitumor response with IDO inhibitors to enhance the antitumoral effect of immunomodulatory vaccines. Here, IDO1 is linked to neoplasm.